Inarigivir soproxil/tenofovir disoproxil fumarate - Spring Bank Pharmaceuticals

Alternative Names: Inarigivir soproxil/tenofovir disoproxil fumarate; SB 11399; SB 9200/tenofovir disoproxil fumarate; SB 9225

Latest Information Update: 28 Mar 2018

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Spring Bank Pharmaceuticals
Class Antiretrovirals; Antivirals; Nucleotides; Phosphonic acids; Purines; Small molecules
Mechanism of Action DDX58 protein stimulants; NOD2 protein antagonists; Nucleotide reverse transcriptase inhibitors; Virus replication inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Clinical Phase Unknown Hepatitis B

Most Recent Events

28 Mar 2018 Chemical structure information added
20 Feb 2018 Spring Bank Pharmaceuticals plans a phase III trial for Hepatitis B in USA in 2019 (CTP#294220)
12 Oct 2017 Clinical trials in Hepatitis B in USA (PO) before October 2017 (Spring Bank Pharmaceuticals pipeline, October 2017)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.